Integra Lifesciences (IART) Upgraded at TheStreet

Integra Lifesciences (NASDAQ:IART) was upgraded by analysts at TheStreet from a “c+” rating to a “b-” rating in a research note issued to investors on Wednesday.

Other equities analysts also recently issued research reports about the stock. Oppenheimer restated a “buy” rating on shares of Integra Lifesciences in a research note on Thursday, January 11th. UBS Group restated a “buy” rating and issued a $57.00 price objective on shares of Integra Lifesciences in a research note on Tuesday, October 31st. Wells Fargo & Co cut shares of Integra Lifesciences from an “outperform” rating to a “market perform” rating in a report on Sunday, October 29th. Zacks Investment Research cut shares of Integra Lifesciences from a “buy” rating to a “hold” rating in a report on Wednesday, October 25th. Finally, Jefferies Group reaffirmed a “buy” rating and issued a $58.00 target price on shares of Integra Lifesciences in a report on Thursday, October 12th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and three have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $52.70.

Integra Lifesciences (NASDAQ:IART) traded up $0.19 during midday trading on Wednesday, reaching $49.34. 797,747 shares of the company’s stock traded hands, compared to its average volume of 493,617. The company has a quick ratio of 3.39, a current ratio of 4.49 and a debt-to-equity ratio of 1.26. Integra Lifesciences has a one year low of $40.51 and a one year high of $56.42. The firm has a market capitalization of $3,890.00, a P/E ratio of 80.89, a PEG ratio of 1.57 and a beta of 0.67.

In other news, VP Richard D. Gorelick sold 1,500 shares of the company’s stock in a transaction dated Tuesday, November 14th. The shares were sold at an average price of $47.19, for a total value of $70,785.00. Following the completion of the sale, the vice president now directly owns 21,665 shares of the company’s stock, valued at $1,022,371.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 21.50% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Prudential Financial Inc. raised its holdings in Integra Lifesciences by 3.3% during the third quarter. Prudential Financial Inc. now owns 105,836 shares of the life sciences company’s stock worth $5,343,000 after purchasing an additional 3,340 shares in the last quarter. Jennison Associates LLC raised its holdings in Integra Lifesciences by 48.3% during the third quarter. Jennison Associates LLC now owns 1,034,702 shares of the life sciences company’s stock worth $52,232,000 after purchasing an additional 336,930 shares in the last quarter. First Trust Advisors LP raised its holdings in Integra Lifesciences by 216.1% during the third quarter. First Trust Advisors LP now owns 51,084 shares of the life sciences company’s stock worth $2,579,000 after purchasing an additional 34,925 shares in the last quarter. UBS Asset Management Americas Inc. raised its holdings in Integra Lifesciences by 7.8% during the second quarter. UBS Asset Management Americas Inc. now owns 43,031 shares of the life sciences company’s stock worth $2,346,000 after purchasing an additional 3,124 shares in the last quarter. Finally, Voya Investment Management LLC raised its holdings in Integra Lifesciences by 30.0% during the second quarter. Voya Investment Management LLC now owns 28,469 shares of the life sciences company’s stock worth $1,552,000 after purchasing an additional 6,571 shares in the last quarter. 87.14% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Integra Lifesciences (IART) Upgraded at TheStreet” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://www.americanbankingnews.com/2018/02/10/integra-lifesciences-iart-upgraded-at-thestreet.html.

About Integra Lifesciences

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Analyst Recommendations for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply